BRAFTOVI
Identification of Braftovi
No description |
Google image searchProduct monograph
Active ingredient
encorafenib, 75 MG
DIN: 02513099
Dosage form(s): CAPSULE
Route(s) of administration: ORAL
Schedule: Prescription
Company: PFIZER CANADA ULC
Date: 05-JUL-2021
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01E — PROTEIN KINASE INHIBITORS (ATC, ATC/DDD)
- L01EC — B-Raf serine-threonine kinase (BRAF) inhibitors (ATC, ATC/DDD)
- L01EC03 — ENCORAFENIB (ATC/DDD)
Reference brand drug: Braftovi